Local treatment of infectious and noninfectious intermediate, posterior, and panuveitis: current concepts and emerging therapeutics.
Identifieur interne : 000097 ( Main/Exploration ); précédent : 000096; suivant : 000098Local treatment of infectious and noninfectious intermediate, posterior, and panuveitis: current concepts and emerging therapeutics.
Auteurs : Akshay S. Thomas [États-Unis] ; Phoebe Lin [États-Unis]Source :
- Current opinion in ophthalmology [ 1531-7021 ] ; 2020.
Descripteurs français
- KwdFr :
- Anti-infectieux (usage thérapeutique), Fluocinolone acétonide (administration et posologie), Glucocorticoïdes (administration et posologie), Humains (MeSH), Immunosuppresseurs (usage thérapeutique), Implant pharmaceutique (MeSH), Infections bactériennes de l'oeil (microbiologie), Infections bactériennes de l'oeil (traitement médicamenteux), Méthotrexate (usage thérapeutique), Panuvéite (microbiologie), Panuvéite (traitement médicamenteux), Rituximab (usage thérapeutique), Sirolimus (usage thérapeutique), Uvéite intermédiaire (microbiologie), Uvéite intermédiaire (traitement médicamenteux), Uvéite postérieure (microbiologie), Uvéite postérieure (traitement médicamenteux).
- MESH :
- administration et posologie : Fluocinolone acétonide, Glucocorticoïdes.
- microbiologie : Infections bactériennes de l'oeil, Panuvéite, Uvéite intermédiaire, Uvéite postérieure.
- traitement médicamenteux : Infections bactériennes de l'oeil, Panuvéite, Uvéite intermédiaire, Uvéite postérieure.
- usage thérapeutique : Anti-infectieux, Immunosuppresseurs, Méthotrexate, Rituximab, Sirolimus.
- Humains, Implant pharmaceutique.
English descriptors
- KwdEn :
- Anti-Infective Agents (therapeutic use), Drug Implants (MeSH), Eye Infections, Bacterial (drug therapy), Eye Infections, Bacterial (microbiology), Fluocinolone Acetonide (administration & dosage), Glucocorticoids (administration & dosage), Humans (MeSH), Immunosuppressive Agents (therapeutic use), Methotrexate (therapeutic use), Panuveitis (drug therapy), Panuveitis (microbiology), Rituximab (therapeutic use), Sirolimus (therapeutic use), Uveitis, Intermediate (drug therapy), Uveitis, Intermediate (microbiology), Uveitis, Posterior (drug therapy), Uveitis, Posterior (microbiology).
- MESH :
- chemical , administration & dosage : Fluocinolone Acetonide, Glucocorticoids.
- chemical , therapeutic use : Anti-Infective Agents, Immunosuppressive Agents, Methotrexate, Rituximab, Sirolimus.
- chemical : Drug Implants.
- drug therapy : Eye Infections, Bacterial, Panuveitis, Uveitis, Intermediate, Uveitis, Posterior.
- microbiology : Eye Infections, Bacterial, Panuveitis, Uveitis, Intermediate, Uveitis, Posterior.
- Humans.
Abstract
PURPOSE OF REVIEW
Local therapeutics play an important role in the management of infectious and noninfectious uveitis (NIU) as well as certain masquerade syndromes. This review highlights the established therapeutics and those under investigation for the management of uveitis.
RECENT FINDINGS
An injectable long-acting fluocinolone acetonide insert was recently approved by the Food and Drug Administration for the treatment of NIU affecting the posterior segment. Intravitreal methotrexate, sirolimus, and anti-vascular endothelial growth factor (VEGF) agents are being evaluated for efficacy in NIU. Intravitreal foscarnet and ganciclovir are important adjuncts in the treatment of viral retinitis as are methotrexate and rituximab for the management of vitreoretinal lymphoma.
SUMMARY
Local injectable steroids with greater durability are now available for NIU but comparative efficacy to other treatment modalities remains to be determined. Local steroid-sparing immunosuppressive agents are undergoing evaluation for efficacy in NIU as are anti-VEGF agents for uveitic macular edema. Local antivirals may improve outcomes in cases of viral retinitis. Local chemotherapeutics can help induce remission in vitreoretinal lymphoma.
DOI: 10.1097/ICU.0000000000000651
PubMed: 32168001
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Local treatment of infectious and noninfectious intermediate, posterior, and panuveitis: current concepts and emerging therapeutics.</title><author><name sortKey="Thomas, Akshay S" sort="Thomas, Akshay S" uniqKey="Thomas A" first="Akshay S" last="Thomas">Akshay S. Thomas</name><affiliation wicri:level="2"><nlm:affiliation>Tennessee Retina, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Tennessee Retina, Nashville</wicri:cityArea></affiliation></author><author><name sortKey="Lin, Phoebe" sort="Lin, Phoebe" uniqKey="Lin P" first="Phoebe" last="Lin">Phoebe Lin</name><affiliation wicri:level="2"><nlm:affiliation>Casey Eye Institute, Oregon Health and Science University, Portland, Oregon, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Casey Eye Institute, Oregon Health and Science University, Portland, Oregon</wicri:regionArea><placeName><region type="state">Oregon</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32168001</idno><idno type="pmid">32168001</idno><idno type="doi">10.1097/ICU.0000000000000651</idno><idno type="wicri:Area/Main/Corpus">000103</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000103</idno><idno type="wicri:Area/Main/Curation">000103</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000103</idno><idno type="wicri:Area/Main/Exploration">000103</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Local treatment of infectious and noninfectious intermediate, posterior, and panuveitis: current concepts and emerging therapeutics.</title><author><name sortKey="Thomas, Akshay S" sort="Thomas, Akshay S" uniqKey="Thomas A" first="Akshay S" last="Thomas">Akshay S. Thomas</name><affiliation wicri:level="2"><nlm:affiliation>Tennessee Retina, Nashville, Tennessee.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Tennessee Retina, Nashville</wicri:cityArea></affiliation></author><author><name sortKey="Lin, Phoebe" sort="Lin, Phoebe" uniqKey="Lin P" first="Phoebe" last="Lin">Phoebe Lin</name><affiliation wicri:level="2"><nlm:affiliation>Casey Eye Institute, Oregon Health and Science University, Portland, Oregon, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Casey Eye Institute, Oregon Health and Science University, Portland, Oregon</wicri:regionArea><placeName><region type="state">Oregon</region></placeName></affiliation></author></analytic><series><title level="j">Current opinion in ophthalmology</title><idno type="eISSN">1531-7021</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Infective Agents (therapeutic use)</term><term>Drug Implants (MeSH)</term><term>Eye Infections, Bacterial (drug therapy)</term><term>Eye Infections, Bacterial (microbiology)</term><term>Fluocinolone Acetonide (administration & dosage)</term><term>Glucocorticoids (administration & dosage)</term><term>Humans (MeSH)</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Methotrexate (therapeutic use)</term><term>Panuveitis (drug therapy)</term><term>Panuveitis (microbiology)</term><term>Rituximab (therapeutic use)</term><term>Sirolimus (therapeutic use)</term><term>Uveitis, Intermediate (drug therapy)</term><term>Uveitis, Intermediate (microbiology)</term><term>Uveitis, Posterior (drug therapy)</term><term>Uveitis, Posterior (microbiology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anti-infectieux (usage thérapeutique)</term><term>Fluocinolone acétonide (administration et posologie)</term><term>Glucocorticoïdes (administration et posologie)</term><term>Humains (MeSH)</term><term>Immunosuppresseurs (usage thérapeutique)</term><term>Implant pharmaceutique (MeSH)</term><term>Infections bactériennes de l'oeil (microbiologie)</term><term>Infections bactériennes de l'oeil (traitement médicamenteux)</term><term>Méthotrexate (usage thérapeutique)</term><term>Panuvéite (microbiologie)</term><term>Panuvéite (traitement médicamenteux)</term><term>Rituximab (usage thérapeutique)</term><term>Sirolimus (usage thérapeutique)</term><term>Uvéite intermédiaire (microbiologie)</term><term>Uvéite intermédiaire (traitement médicamenteux)</term><term>Uvéite postérieure (microbiologie)</term><term>Uvéite postérieure (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Fluocinolone Acetonide</term><term>Glucocorticoids</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Infective Agents</term><term>Immunosuppressive Agents</term><term>Methotrexate</term><term>Rituximab</term><term>Sirolimus</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Drug Implants</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Fluocinolone acétonide</term><term>Glucocorticoïdes</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Eye Infections, Bacterial</term><term>Panuveitis</term><term>Uveitis, Intermediate</term><term>Uveitis, Posterior</term></keywords><keywords scheme="MESH" qualifier="microbiologie" xml:lang="fr"><term>Infections bactériennes de l'oeil</term><term>Panuvéite</term><term>Uvéite intermédiaire</term><term>Uvéite postérieure</term></keywords><keywords scheme="MESH" qualifier="microbiology" xml:lang="en"><term>Eye Infections, Bacterial</term><term>Panuveitis</term><term>Uveitis, Intermediate</term><term>Uveitis, Posterior</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections bactériennes de l'oeil</term><term>Panuvéite</term><term>Uvéite intermédiaire</term><term>Uvéite postérieure</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anti-infectieux</term><term>Immunosuppresseurs</term><term>Méthotrexate</term><term>Rituximab</term><term>Sirolimus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Implant pharmaceutique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>PURPOSE OF REVIEW</b></p><p>Local therapeutics play an important role in the management of infectious and noninfectious uveitis (NIU) as well as certain masquerade syndromes. This review highlights the established therapeutics and those under investigation for the management of uveitis.</p></div><div type="abstract" xml:lang="en"><p><b>RECENT FINDINGS</b></p><p>An injectable long-acting fluocinolone acetonide insert was recently approved by the Food and Drug Administration for the treatment of NIU affecting the posterior segment. Intravitreal methotrexate, sirolimus, and anti-vascular endothelial growth factor (VEGF) agents are being evaluated for efficacy in NIU. Intravitreal foscarnet and ganciclovir are important adjuncts in the treatment of viral retinitis as are methotrexate and rituximab for the management of vitreoretinal lymphoma.</p></div><div type="abstract" xml:lang="en"><p><b>SUMMARY</b></p><p>Local injectable steroids with greater durability are now available for NIU but comparative efficacy to other treatment modalities remains to be determined. Local steroid-sparing immunosuppressive agents are undergoing evaluation for efficacy in NIU as are anti-VEGF agents for uveitic macular edema. Local antivirals may improve outcomes in cases of viral retinitis. Local chemotherapeutics can help induce remission in vitreoretinal lymphoma.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">32168001</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-7021</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>Current opinion in ophthalmology</Title><ISOAbbreviation>Curr Opin Ophthalmol</ISOAbbreviation></Journal><ArticleTitle>Local treatment of infectious and noninfectious intermediate, posterior, and panuveitis: current concepts and emerging therapeutics.</ArticleTitle><Pagination><MedlinePgn>174-184</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/ICU.0000000000000651</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">Local therapeutics play an important role in the management of infectious and noninfectious uveitis (NIU) as well as certain masquerade syndromes. This review highlights the established therapeutics and those under investigation for the management of uveitis.</AbstractText><AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">An injectable long-acting fluocinolone acetonide insert was recently approved by the Food and Drug Administration for the treatment of NIU affecting the posterior segment. Intravitreal methotrexate, sirolimus, and anti-vascular endothelial growth factor (VEGF) agents are being evaluated for efficacy in NIU. Intravitreal foscarnet and ganciclovir are important adjuncts in the treatment of viral retinitis as are methotrexate and rituximab for the management of vitreoretinal lymphoma.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">Local injectable steroids with greater durability are now available for NIU but comparative efficacy to other treatment modalities remains to be determined. Local steroid-sparing immunosuppressive agents are undergoing evaluation for efficacy in NIU as are anti-VEGF agents for uveitic macular edema. Local antivirals may improve outcomes in cases of viral retinitis. Local chemotherapeutics can help induce remission in vitreoretinal lymphoma.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Akshay S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Tennessee Retina, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Phoebe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Casey Eye Institute, Oregon Health and Science University, Portland, Oregon, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Opin Ophthalmol</MedlineTA><NlmUniqueID>9011108</NlmUniqueID><ISSNLinking>1040-8738</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000890">Anti-Infective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004343">Drug Implants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0CD5FD6S2M</RegistryNumber><NameOfSubstance UI="D005446">Fluocinolone Acetonide</NameOfSubstance></Chemical><Chemical><RegistryNumber>4F4X42SYQ6</RegistryNumber><NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance></Chemical><Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber><NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance></Chemical><Chemical><RegistryNumber>YL5FZ2Y5U1</RegistryNumber><NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000890" MajorTopicYN="N">Anti-Infective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004343" MajorTopicYN="N">Drug Implants</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015818" MajorTopicYN="N">Eye Infections, Bacterial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005446" MajorTopicYN="N">Fluocinolone Acetonide</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008727" MajorTopicYN="N">Methotrexate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015864" MajorTopicYN="N">Panuveitis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015867" MajorTopicYN="N">Uveitis, Intermediate</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015866" MajorTopicYN="N">Uveitis, Posterior</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32168001</ArticleId><ArticleId IdType="doi">10.1097/ICU.0000000000000651</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Oregon</li><li>Tennessee</li></region></list><tree><country name="États-Unis"><region name="Tennessee"><name sortKey="Thomas, Akshay S" sort="Thomas, Akshay S" uniqKey="Thomas A" first="Akshay S" last="Thomas">Akshay S. Thomas</name></region><name sortKey="Lin, Phoebe" sort="Lin, Phoebe" uniqKey="Lin P" first="Phoebe" last="Lin">Phoebe Lin</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000097 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000097 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= RapamycinFungusV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32168001
|texte= Local treatment of infectious and noninfectious intermediate, posterior, and panuveitis: current concepts and emerging therapeutics.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32168001" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a RapamycinFungusV1
| This area was generated with Dilib version V0.6.38. |  |